Top

Published in:

01-04-2010 | Review Article

Predictive factors for anthracycline-based chemotherapy for human breast cancer

Authors: Yasuo Miyoshi, Masafumi Kurosumi, Junichi Kurebayashi, Nariaki Matsuura, Masato Takahashi, Eriko Tokunaga, Chiyomi Egawa, Norikazu Masuda, Seishi Kono, Koji Morimoto, Seung Jin Kim, Masatsugu Okishiro, Tetsu Yanagisawa, Satsuki Ueda, Tetsuya Taguchi, Yasuhiro Tamaki, Shinzaburo Noguchi

Published in: Breast Cancer | Issue 2/2010

Abstract

Predictive factors for anthracycline-based chemotherapy have yet to be incorporated into daily practice. Meta-analyses of studies using anthracycline-based treatment regimens have shown an improved prognosis for human epidermal growth factor receptor type 2 (HER2)-positive tumors, but not for HER2-negative tumors compared with results of non-anthracycline regimens. Currently it is believed that the positive association between HER2 status and anthracycline sensitivity is indirect, that is, their association may be mediated through topoisomerase II alpha (TOP2A), a target molecule of anthracyclines, since TOP2A is near HER-2 and co-amplification of the TOP2A gene frequently occurs in HER2-amplified tumors. This strongly suggests that TOP2A gene amplification is a predictive factor for anthracyline-based regimens. The Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society has demonstrated that TOP2A-positive and BRCA1-negative subsets evaluated by immunohistochemical staining show a significantly higher pathological complete response when treated with preoperative epirubicin-containing regimens. Combining these findings with the observation that triple-negative tumors and basal-like tumors respond to anthracycline treatment suggests that not only HER2-positive tumors but also a distinct subset of HER2-negative tumors may be sensitive to anthracycline-based regimens.

Jones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24:5381–7.CrossRefPubMed

Wang JC. DNA topoisomerases. Annu Rev Biochem. 1996;65:635–92.CrossRefPubMed

Cummings J, Smyth JF. DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol. 1993;4:533–43.PubMed

Vincent-Salomon A, Rousseau A, Jouve M, Beuzeboc P, Sigal-Zafrani B, Freneaux P, et al. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer. 2004;40:1502–8.CrossRefPubMed

Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–9.PubMed

Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH. Primary systemic therapy of breast cancer. Oncologist. 2006;11:574–89.CrossRefPubMed

Veneroni S, Zaffaroni N, Daidone MG, Benini E, Villa R, Silvestrini R. Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer. 1994;30A:1002–7.CrossRefPubMed

Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res. 2000;6:50–6.PubMed

Pani G, Bedogni B, Anzevino R, Colavitti R, Palazzotti B, Borrello S, et al. Deregulated manganese superoxide dismutase expression and resistance to oxidative injury in p53-deficient cells. Cancer Res. 2000;60:4654–60.PubMed

10.

Penault-Llorca F, Cayre A, Bouchet Mishellany F, Amat S, Feillel V, Le Bouedec G, et al. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol. 2003;22:1319–25.PubMed

11.

Park K, Kim J, Lim S, Han S. Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer. 2003;39:631–4.CrossRefPubMed

12.

Pritchard KI, Shepherd LE, O’Malley FP, Andrulis IL, Tu D, Bramwell VH, et al. National cancer institute of Canada clinical trials group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006;354:2103–11.CrossRefPubMed

13.

Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O’Malley F, Dhesy-Thind B. HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol. 2008;26:736–44.CrossRefPubMed

14.

Järvinen TA, Tanner M, Rantanen V, Bärlund M, Borg A, Grénman S, et al. Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 2000;156:839–47.PubMed

15.

Durbecq V, Desmed C, Paesmans M, Cardoso F, Di Leo A, Mano M, et al. Correlation between topoisomerase-II alpha gene amplification and protein expression in HER-2 amplified breast cancer. Int J Oncol. 2004;25:1473–9.PubMed

16.

Cardoso F, Durbecq V, Larsimont D, Paesmans M, Leroy JY, Rouas G, et al. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol. 2004;24:201–9.PubMed

17.

Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, et al. HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res. 2002;8:1107–16.PubMed

18.

Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, et al. Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res. 2002;8:1061–7.PubMed

19.

Villman K, Sjöström J, Heikkilä R, Hultborn R, Malmström P, Bengtsson NO, et al. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer. Acta Oncol. 2006;45:590–6.CrossRefPubMed

20.

Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, et al. Topoisomerase II alpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. Breast. 2008;17:506–11.CrossRefPubMed

21.

Manna Edel F, Teixeira LC, Alvarenga M. Association between immunohistochemical expression of topoisomerase II alpha, HER2 and hormone receptors and response to primary chemotherapy in breast cancer. Tumori. 2006;92:222–9.PubMed

22.

MacGrogan G, Rudolph P, Mascarel Id I, Mauriac L, Durand M, Avril A, et al. DNA topoisomerase II alpha expression and the response to primary chemotherapy in breast cancer. Br J Cancer. 2003;89:666–71.CrossRefPubMed

23.

Martin-Richard M, Muñoz M, Albanell J, Colomo L, Bellet M, Rey MJ, et al. Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. Oncology. 2004;66:388–94.CrossRefPubMed

24.

Durbecq V, Paesmans M, Cardoso F, Desmedt C, Di Leo A, Chan S, et al. Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther. 2004;3:1207–14.PubMed

25.

Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, et al. Topoisomerase II alpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers. Cancer Lett. 2008;264:44–53.CrossRefPubMed

26.

Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004;40:205–11.CrossRefPubMed

27.

Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish breast cancer cooperative group. J Clin Oncol. 2005;23:7483–90.CrossRefPubMed

28.

Scandinavian Breast Group Trial 9401, Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, et al. Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian breast group trial 9401. J Clin Oncol. 2006;24:2428–36.CrossRefPubMed

29.

Rudolph P, MacGrogan G, Bonichon F, Frahm SO, de Mascarel I, Trojani M, et al. Prognostic significance of Ki-67 and topoisomerase II alpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases. Breast Cancer Res Treat. 1999;55:61–71.CrossRefPubMed

30.

Delaloge S, Pautier P, Kloos I. BRCA1-linked breast cancer (BC) is highly more chemosensitive than its BRCA2-linked or sporadic counterparts. Paper presented at 27th congress of the European society for medical oncology, 18–22 October 2002, Nice, France. 2002; Abstract 120.

31.

Goffin JR, Chappuis PO, Bégin LR, Wong N, Brunet JS, Hamel N, et al. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer. 2003;97:527–36.CrossRefPubMed

32.

Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol. 2003;22:1169–73.PubMed

33.

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275–81.CrossRefPubMed

34.

Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678–85.CrossRefPubMed

35.

Conforti R, Boulet T, Tomasic G, Taranchon E, Arriagada R, Spielmann M, et al. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. Ann Oncol. 2007;18:1477–83.CrossRefPubMed

36.

Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, et al. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat. 2007;106:181–9.CrossRefPubMed

Title: Predictive factors for anthracycline-based chemotherapy for human breast cancer
Authors: Yasuo Miyoshi
Masafumi Kurosumi
Junichi Kurebayashi
Nariaki Matsuura
Masato Takahashi
Eriko Tokunaga
Chiyomi Egawa
Norikazu Masuda
Seishi Kono
Koji Morimoto
Seung Jin Kim
Masatsugu Okishiro
Tetsu Yanagisawa
Satsuki Ueda
Tetsuya Taguchi
Yasuhiro Tamaki
Shinzaburo Noguchi
Publication date: 01-04-2010
Publisher: Springer Japan
Published in: Breast Cancer / Issue 2/2010
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-009-0152-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Tumor reduction rate predicts early recurrence in patients with breast cancer failing to achieve complete response to primary chemotherapy

Breast cancer stem cells

A case of a giant phyllodes tumor of the breast with hypoglycemia caused by high-molecular-weight insulin-like growth factor II

Malignant neoplasm in the axilla of a male: suspected primary carcinoma of an accessory mammary gland

Breast cancer research from bench to bedside

Prediction of hormone sensitivity for breast cancers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer